Aktis Oncology, Inc., a clinical-stage oncology company focused on targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, appointed Kyle Kuvalanka as Chief Financial Officer (CFO). The appointment strengthens Aktis’ financial and corporate development leadership as the company advances its clinical pipeline and corporate growth initiatives.

Kuvalanka brings over 20 years of substantial senior leadership experience in the biopharmaceutical sector, as well as an extensive understanding of capital markets. Since 2013, he has served as a C-level leader at clinical- and preclinical-stage biotechnology companies. 

Most recently, he served as CFO and Chief Business Officer (CBO) at ROME Therapeutics and as CFO and Chief Operating Officer (COO) at Goldfinch Bio. Prior, Kuvalanka served as COO at Syros Pharmaceuticals and CBO at Blueprint Medicines, where, for both companies, he built and led the finance and business functions and guided the companies’ initial public offerings. 

Earlier in his career, Kuvalanka served as Vice President, Business Development, Corporate Strategy, and Alliance Management at Millennium Pharmaceuticals, the Takeda Oncology Company, and as Vice President, Investor Relations at Millennium Pharmaceuticals.

“Kyle is a proven leader with deep expertise in biopharmaceutical finance, business development, and corporate affairs,” said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology. “He has raised over $700 million in capital and has led numerous transactions to build and grow clinical- and commercial-stage companies, both public and private. Kyle’s joining the Aktis leadership team is timely as we further advance our novel pipeline of innovative miniprotein radioconjugates, including bringing our second program into the clinic in the coming year.”